Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration

被引：8

作者：

Mussolin, Lara ^{[1
,2
]}

Lovisa, Federica ^{[1
,2
]}

Gallingani, Ilaria ^{[1
]}

Cavallaro, Elena ^{[1
]}

Carraro, Elisa ^{[1
]}

Damanti, Carlotta C. ^{[1
]}

Vinti, Luciana ^{[3
]}

Sala, Alessandra ^{[4
]}

Micalizzi, Concetta ^{[5
]}

Santoro, Nicola ^{[6
]}

Piglione, Matilde ^{[7
]}

Cellini, Monica ^{[8
]}

Buffardi, Salvatore ^{[9
]}

Buldini, Barbara ^{[1
]}

D'Amore, Emanuele S. G. ^{[10
]}

Biffi, Alessandra ^{[1
,2
,11
]}

Pillon, Marta ^{[1
]}

机构：

[1] Univ Padua, Div Pediat Hematol Oncol & Stem Cell Transplant, Dept Women & Child Hlth, Padua, Italy

[2] Ist Ric Pediat Citta Speranza, Padua, Italy

[3] Bambino Gesu Pediat Hosp, Dept Pediat Hematooncol, Rome, Italy

[4] Univ Milano Bicocca, Dept Paediat, Fdn MBBM, Azienda Osped S Gerardo, Monza, Italy

[5] IRCCS Ist Giannina Gaslini, Dept Paediat Haematooncol, Genoa, Italy

[6] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy

[7] Univ Hosp Citta Salute & Sci Torino, Dept Paediat, Paediat Haematol, Turin, Italy

[8] Policlin Hosp, Div Paediat Oncol Haematol, Modena, Italy

[9] Santobono Pausilipon Childrens Hosp, Dept Paediat Haematooncol, Naples, Italy

[10] San Bortolo Hosp, Dept Pathol, Vicenza, Italy

[11] Dana Farber Boston Childrens Canc & Blood Disorde, Gene Therapy Program, Boston, MA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 03期

关键词：

B-cell acute leukaemia; Burkitt; AIEOP LNH-97; anti-CD20; paediatric; minimal residual disease; NON-HODGKIN-LYMPHOMA; ACUTE-LYMPHOBLASTIC-LEUKEMIA; CHILDREN; ADOLESCENTS; RITUXIMAB; BURKITT; CHEMOTHERAPY; LYMPHOMA/LEUKAEMIA; INTERMEDIATE; THERAPY;

D O I：

10.1111/bjh.16531

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E108 / E111

页数：4

共 32 条

[21] Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy
Sean A. Freeman
Bruno Lemarchant
Tifanie Alberto
Julie Boucher
Olivier Outteryck
Myriam Labalette
Stéphanie Rogeau
Sylvain Dubucquoi
Hélène Zéphir
Neurotherapeutics, 2023, 20 : 1707 - 1722
[22] Pharmacokinetics (PK) of the chimeric anti-CD20 antibody (MAB) IDEC-C2B8: Analysis of serum concentrations in patients (PTS) with relapsed B-cell lymphoma
Rosenberg, J
Waldichuk, C
GrilloLopez, AJ
Leonard, JE
Dallaire, BK
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1071 - 1071
[23] RADIOIMMUNOTHERAPY OF CUTANEOUS B-CELL LYMPHOMA WITH [I-131] ANTI-B1 (ANTI-CD20) ANTIBODY INDUCES A NOVEL CUTANEOUS REACTION PATTERN ASSOCIATED WITH COMPLETE REMISSION OF CUTANEOUS DISEASE
STEVENS, SR
COOPER, KD
WAHL, RL
ROSS, CW
SINGLETON, TP
KAMINSKI, MS
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (04) : 563 - 563
[24] Pathogenic analysis of infusion-related severe refractory shock in diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20.
Gutierrez, A
Rodriguez, J
Galmes, B
Ramos, R
Amezaga, R
Gomez, D
Pons, J
Terrasa, F
Ferrer, J
Sampol, A
Morey, M
Duran, MA
Novo, A
Besalduch, J
BLOOD, 2003, 102 (11) : 302B - 302B
[25] The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody
Maruyama, Shuhei
Wada, Daiki
Kanayama, Shuji
Shimazu, Haruka
Miyano, Yumiko
Inoue, Akira
Kashihara, Masami
Okuda, Kazuyuki
Saito, Fukuki
Nakamori, Yasushi
Ishii, Kazuyoshi
Kuwagata, Yasuyuki
BMC INFECTIOUS DISEASES, 2024, 24 (01)
[26] Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia
Fleming, Shaun
Venn, Nicola
Reynolds, John
Nguyen, Uyen
Kwan, John
Moore, John
Yeung, David T.
Leahy, Michael F.
Greenwood, Matthew
Verner, Emma
Bajel, Ashish
Berkahn, Leanne
Wei, Andrew H.
Sutton, Rosemary
BLOOD, 2019, 134
[27] European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma (vol 18, pg 317, 2000)
Foran
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) : 2006 - 2006
[28] Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -: early stopping after the first interim analysis.
Pfreundschuh, MG
Trümper, L
Ma, D
Österborg, A
Pettengell, R
Trneny, M
Shepherd, L
Waleswski, J
Zinzani, PL
Loeffler, M
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 558S - 558S
[29] Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
Raymund Buhmann
Stanglmaier Michael
Hess Juergen
Lindhofer Horst
Christian Peschel
Hans-Jochem Kolb
Journal of Translational Medicine, 11
[30] Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
Buhmann, Raymund
Michael, Stanglmaier
Juergen, Hess
Horst, Lindhofer
Peschel, Christian
Kolb, Hans-Jochem
JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11

← 1 2 3 4 →